Home › Eisai And Biogen Idec Enter Collaboration To Develop And Commercialize Alzheimer's Disease Treatments
 

Keywords :   


Eisai And Biogen Idec Enter Collaboration To Develop And Commercialize Alzheimer's Disease Treatments

2014-03-05 05:29:31| drugdiscoveryonline News Articles

Eisai Co., Ltd. and Biogen Idec recently announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401

Tags: enter develop disease collaboration

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Water investors have withdrawn billions, says research
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
More »